VINZENZ GRUPPE
     
 

Prospective comparison of flecainide versus sotalol for immediate cardioversion of atrial fibrillation.

Reisinger, J, Gatterer, E, Heinze, G, Wiesinger, K, Zeindlhofer, E, Gattermeier, M, Poelzl, G, Kratzer, H, Ebner, A, Hohenwallner, W, Lenz, K, Slany, J and Kuhn, P (1998) Prospective comparison of flecainide versus sotalol for immediate cardioversion of atrial fibrillation. The American journal of cardiology, 81 (12). pp. 1450-4. ISSN 0002-9149

Full text not available from this repository.

Abstract

This study sought to compare the efficacy and safety of intravenous flecainide and sotalol for immediate cardioversion of atrial fibrillation. We performed a prospective, randomized, single-blind, multicenter trial, including 106 hemodynamically stable patients with atrial fibrillation, stratified according to duration of the arrhythmia. Exclusion criteria included severely reduced left ventricular systolic function, recent antiarrhythmic therapy, and hypokalemia. Patients were randomly assigned to receive either intravenous flecainide or intravenous sotalol. Trial medication was given at a dose of 1.5 mg/kg body weight (maximum 150 mg). Overall, 28 of 54 patients (52%) given flecainide and 12 of 52 patients (23%) given sotalol converted to sinus rhythm during the first 2 hours after start of the infusion (p = 0.003). Multivariate analysis confirmed that treatment allocation to flecainide, an arrhythmia duration of < or = 24 hours, higher plasma magnesium level at baseline, higher age for men, and lower age for women independently increases the probability of conversion. The frequency of adverse effects was not significantly different in the 2 treatment groups.
Item Type: Article
Subjects: WG Kardiovaskuläres System
Depositing User: Dr. Christian Vogel
Date Deposited: 15 Nov 2012 09:14
Last Modified: 15 Nov 2012 09:14
URI: http://eprints.vinzenzgruppe.at/id/eprint/10

Actions (login required)

View Item
View Item